Circulating NKp46⁺ Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer

References

• Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene. 2008;27(45):5932–5943. doi:10.1038/onc.2008.267.
   PubMed Web of Science ®Google Scholar
• Guillerey C, Mj S. NK Cells and Cancer Immunoediting. Curr Top Microbiol Immunol. 2016;395:115–145. doi: 10.1007/82_2015_446.
   PubMed Web of Science ®Google Scholar
• Del Zotto G, Marcenaro E, Vacca P, Sivori S, Pende D, Della Chiesa M, Moretta F, Ingegnere T, Mingari MC, Moretta A, et al. Markers and function of human NK cells in normal and pathological conditions. Cytometry B Clin Cytom. 2017;92(2):100–114. doi: 10.1002/cyto.b.21508.
   PubMed Web of Science ®Google Scholar
• Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol. 1989. 143(10):3183–3191.
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633–640. doi:10.1016/S1471-4906(01)02060-9.
   PubMed Web of Science ®Google Scholar
• Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C, et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med. 2009;206(7):1495–1503. doi: 10.1084/jem.20090681.
   PubMed Web of Science ®Google Scholar
• Hecht M-L, Rosental B, Horlacher T, Hershkovitz O, De Paz JL, Noti C, Schauer S, Porgador A, Seeberger PH. Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences. J Proteome Res. 2009;8(2):712–720. doi:10.1021/pr800747c.
   PubMed Web of Science ®Google Scholar
• El-Gazzar A, Groh V, Spies T. Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer. J Immunol. 2013;191(4):1509–1515. doi:10.4049/jimmunol.1301071.
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001. 97(10):3146–3151.
   PubMed Web of Science ®Google Scholar
• Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126(4):458. doi:10.1111/j.1365-2567.2008.03027.x.
   PubMed Web of Science ®Google Scholar
• Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9(5):503–510. doi:10.1038/ni1582.
   PubMed Web of Science ®Google Scholar
• Michel T, Poli A, Cuapio A, Briquemont B, Iserentant G, Ollert M, Human ZJ. CD56bright NK Cells: an Update. J Immunol. 2016;196(7):2923–2931. doi:10.4049/jimmunol.1502570.
   PubMed Web of Science ®Google Scholar
• Penczek A, Sienczyk M, Wirtz CR, Burster T. Cell surface cathepsin G activity differs between human natural killer cell subsets. Immunol Lett. 2016;179:80–84. doi: 10.1016/j.imlet.2016.09.010.
   PubMed Web of Science ®Google Scholar
• Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA, Moreno M. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 1997. 79(12):2320–2328.
   PubMed Web of Science ®Google Scholar
• Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, Aridome K, Hokita S, Aikou T. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. 2000. 88(3):577–583.
   PubMed Web of Science ®Google Scholar
• Villegas FR, Coca S, Villarrubia VG, Jiménez R, Chillón MJ, Jareño J, Zuil M, Callol L. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer Amst Neth. 2002. 35(1):23–28.
   PubMed Web of Science ®Google Scholar
• Nieto-Velázquez NG, Torres-Ramos YD, Muñoz-Sánchez JL, Espinosa-Godoy L, Gómez-Cortés S, Moreno J, Moreno-Eutimio MA. Altered Expression of Natural Cytotoxicity Receptors and NKG2D on Peripheral Blood NK Cell Subsets in Breast Cancer Patients. Transl Oncol. 2016;9(5):384–391. doi:10.1016/j.tranon.2016.07.003.
   PubMed Web of Science ®Google Scholar
• Rocca YS, Roberti MP, Juliá EP, Pampena MB, Bruno L, Rivero S, Huertas E, Sánchez Loria F, Pairola A, Caignard A, et al. Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15. Front Immunol. 2016;7. doi: 10.3389/fimmu.2016.00413.
   PubMed Web of Science ®Google Scholar
• Peng Y-P, Zhu Y, Zhang -J-J, Xu Z-K, Qian Z-Y, Dai -C-C, Jiang K-R, Wu J-L, Gao W-T, Li Q, et al. Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer. J Transl Med. 2013;11:262. doi: 10.1186/1479-5876-11-262.
   PubMed Web of Science ®Google Scholar
• Mamessier E, Sylvain A, Bertucci F, Castellano R, Finetti P, Houvenaeghel G, Charaffe-Jaufret E, Birnbaum D, Moretta A, Olive D. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res. 2011;71(21):6621–6632. doi:10.1158/0008-5472.CAN-11-0792.
   PubMed Web of Science ®Google Scholar
• Konjević G, Mirjacić Martinović K, Vuletić A, Jović V, Jurisić V, Babović N, Spuzić I. Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients. Clin Exp Metastasis. 2007;24(1):1–11. doi:10.1007/s10585-006-9043-9.
   PubMed Web of Science ®Google Scholar
• Mamessier E, Sylvain A, Thibult M-L, Houvenaeghel G, Jacquemier J, Castellano R, Gonçalves A, André P, Romagné F, Thibault G, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011;121(9):3609–3622. doi: 10.1172/JCI45816.
   PubMed Web of Science ®Google Scholar
• Shen Y, Shen Y, Lu C, Lu C, Tian W, Tian W, Wang L, Wang L, Cui B, Cui B, et al. Possible association of decreased NKG2D expression levels and suppression of the activity of natural killer cells in patients with colorectal cancer. Int J Oncol. 2012;40(4):1285–1290. doi: 10.3892/ijo.2011.1315.
   PubMed Web of Science ®Google Scholar
• Fregni G, Messaoudene M, Fourmentraux-Neves E, Mazouz-Dorval S, Chanal J, Maubec E, Marinho E, Scheer-Senyarich I, Cremer I, Avril M-F, et al. Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages. PloS One. 2013;8(10):e76928. doi: 10.1371/journal.pone.0076928.
   PubMed Web of Science ®Google Scholar
• Beldi-Ferchiou A, Lambert M, Dogniaux S, Vély F, Vivier E, Olive D, Dupuy S, Levasseur F, Zucman D, Lebbé C, et al. PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget. 2016;7(45):72961–72977. doi: 10.18632/oncotarget.12150.
   PubMedGoogle Scholar
• Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, Peng J, Gao L, Liang X, Ma C. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene. 2017;36(44):6143–6153. doi:10.1038/onc.2017.209.
   PubMed Web of Science ®Google Scholar
• Wang Y, Sun J, Gao W, Song B, Shao Q, Zhao L, Zhang Y, Wang Q, Zhang Y, Qu X. Preoperative Tim‑3 expression on peripheral NK cells is correlated with pathologic TNM staging in colorectal cancer. Mol Med Rep. 2017;15(6):3810–3818. doi:10.3892/mmr.2017.6482.
   PubMed Web of Science ®Google Scholar
• Ip S, Da, Gallois A, Jimenez-Baranda S, Khan S, Ac A, Vk K, Osman I, Bhardwaj N. Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade. Cancer Immunol Res. 2014 Feb 11. doi: 10.1158/2326-6066.CIR-13-0171.
   Web of Science ®Google Scholar
• Crome SQ, Nguyen LT, Lopez-Verges S, Yang SYC, Martin B, Yam JY, Johnson DJ, Nie J, Pniak M, Yen PH, et al. A distinct innate lymphoid cell population regulates tumor-associated T cells. Nat Med. 2017;23(3):368–375. doi: 10.1038/nm.4278.
   PubMed Web of Science ®Google Scholar
• Du N, Zhou J, Lin X, Zhang Y, Yang X, Wang Y, Shu Y. Differential activation of NK cells by influenza A pseudotype H5N1 and 1918 and 2009 pandemic H1N1 viruses. J Virol. 2010;84(15):7822–7831. doi:10.1128/JVI.00069-10.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6(10):715–727. doi:10.1038/nri1936.
   PubMed Web of Science ®Google Scholar
• Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P, André P, M-C D-N, Alifano M, J-F R, et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. 2011;71(16):5412–5422. doi: 10.1158/0008-5472.CAN-10-4179.
   PubMed Web of Science ®Google Scholar
• Le Maux Chansac B, Moretta A, Vergnon I, Opolon P, Lécluse Y, Grunenwald D, Kubin M, Soria J-C, Chouaib S, Mami-Chouaib F. NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol. 2005. 175(9):5790–5798.
   PubMed Web of Science ®Google Scholar
• Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, Ratto GB, Mingari MC, Moretta L, Ferlazzo G. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer. 2008;112(4):863–875. doi:10.1002/cncr.23239.
   PubMed Web of Science ®Google Scholar
• Bruno A, Focaccetti C, Pagani A, Imperatori AS, Spagnoletti M, Rotolo N, Cantelmo AR, Franzi F, Capella C, Ferlazzo G, et al. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia N. Y. N.. 2013;15(2):133–142.
   PubMed Web of Science ®Google Scholar
• Grzywacz B, Kataria N, Verneris MR. CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia. 2007;21(2):356–359. doi:10.1038/sj.leu.2404499.
   PubMed Web of Science ®Google Scholar
• Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D, Luo X, Cooley S, Verneris M, Walcheck B, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood. 2013;121(18):3599–3608. doi: 10.1182/blood-2012-04-425397.
   PubMed Web of Science ®Google Scholar
• Nielsen CM, White MJ, Goodier MR, Riley EM. Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease. Front Immunol. 2013;4:422. doi: 10.3389/fimmu.2013.00422.
   PubMed Web of Science ®Google Scholar
• Krzywinska E, Cornillon A, Allende-Vega N, Vo D-N, Rene C, Lu Z-Y, Pasero C, Olive D, Fegueux N, Ceballos P, et al. CD45 Isoform Profile Identifies Natural Killer (NK) Subsets with Differential Activity. PloS One. 2016;11(4):e0150434. doi: 10.1371/journal.pone.0150434.
   PubMed Web of Science ®Google Scholar
• Celis-Gutierrez J, Boyron M, Walzer T, Pandolfi PP, Jonjić S, Olive D, Dalod M, Vivier E, Nunès JA. Dok1 and Dok2 proteins regulate natural killer cell development and function. Embo J. 2014;33(17):1928–1940. doi:10.15252/embj.201387404.
   PubMed Web of Science ®Google Scholar
• Penack O, Gentilini C, Fischer L, Asemissen AM, Scheibenbogen C, Thiel E, Uharek L. CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia. 2005;19(5):835–840. doi:10.1038/sj.leu.2403704.
   PubMed Web of Science ®Google Scholar
• Takahashi E, Kuranaga N, Satoh K, Habu Y, Shinomiya N, Asano T, Seki S, Hayakawa M. Induction of CD16+ CD56bright NK Cells with Antitumour Cytotoxicity not only from CD16− CD56bright NK Cells but also from CD16− CD56dim NK Cells. Scand J Immunol. 2007;65(2):126–138. doi:10.1111/j.1365-3083.2006.01883.x.
   PubMed Web of Science ®Google Scholar
• Mandelboim O, Porgador A. NKp46. Int J Biochem Cell Biol. 2001;33(12):1147–1150. doi:10.1016/S1357-2725(01)00078-4.
   PubMed Web of Science ®Google Scholar
• Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, Scope A, Neuman T, Enk CD, Hanna JH, et al. NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Immunity. 2018;48(2):396–398. doi: 10.1016/j.immuni.2018.01.010.
   PubMed Web of Science ®Google Scholar
• Fend L, Rusakiewicz S, Adam J, Bastien B, Caignard A, Messaoudene M, Iribarren C, Cremer I, Marabelle A, Borg C, et al. Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. Oncoimmunology. 2017;6(1):e1163456. doi: 10.1080/2162402X.2016.1163456.
   PubMed Web of Science ®Google Scholar
• Fregni G, Perier A, Pittari G, Jacobelli S, Sastre X, Gervois N, Allard M, Bercovici N, Avril MF, Caignard A. Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy. Clin Cancer Res. 2011;17(9):2628–2637. doi:10.1158/1078-0432.CCR-10-2084.
   PubMed Web of Science ®Google Scholar
• Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, Biassoni R, Bottino C, Moretta L, Moretta A. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci. 2003;100(7):4120–4125. doi:10.1073/pnas.0730640100.
   PubMed Web of Science ®Google Scholar
• Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A, Balsamo M, Conte R, Benelli R, Minghelli S, et al. Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity. Cancer Res. 2012;72(6):1407–1415. doi: 10.1158/0008-5472.CAN-11-2544.
   PubMed Web of Science ®Google Scholar
• Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908):734–738. doi:10.1038/nature01112.
   PubMed Web of Science ®Google Scholar
• Salih HR, Rammensee H-G SA. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol. 2002. 169(8):4098–4102.
   PubMed Web of Science ®Google Scholar
• Loyon R, Picard E, Mauvais O, Queiroz L, Mougey V, Pallandre J-R, Galaine J, Mercier-Letondal P, Kellerman G, Chaput N, et al. IL-21-Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor-Dependent Manner. J Immunol. 2016;197(1):85–96. doi: 10.4049/jimmunol.1501147.
   PubMed Web of Science ®Google Scholar
• Martín-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004;5(12):1260–1265. doi:10.1038/ni1138.
   PubMed Web of Science ®Google Scholar
• Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P, Benhamouda N, Cazes A, Le Pimpec-Barthes F, Gaugler B, et al. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res. 2012;18(10):2943–2953. doi: 10.1158/1078-0432.CCR-11-3185.
   PubMed Web of Science ®Google Scholar
• Beziaud L, Mansi L, Ravel P, Marie-Joseph EL, Laheurte C, Rangan L, Bonnefoy F, Pallandre J-R, Boullerot L, Gamonet C, et al. Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity. Cancer Res. 2016;76(14):4100–4112. doi: 10.1158/0008-5472.CAN-15-2452.
   PubMed Web of Science ®Google Scholar
• Kim S, François E, André T, Samalin E, Jary M, Hajbi FE, Baba-Hamed N, Pernot S, Kaminsky M-C, Bouché O, et al. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2018;19(8):1094–1106. doi: 10.1016/S1470-2045(18)30321-8.
   PubMed Web of Science ®Google Scholar
• Wang S, Han X, Hu X, Wang X, Zhao L, Tang L, Feng Y, Wu D, Sun Y, Shi Y. Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients. Clin Chim Acta Int J Clin Chem. 2014;430:63–70. doi: 10.1016/j.cca.2013.12.026.
   PubMed Web of Science ®Google Scholar
• Xu L, Huang Y, Tan L, Yu W, Chen D, Lu C, He J, Wu G, Liu X, Zhang Y. Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol. 2015;29(2):635–641. doi:10.1016/j.intimp.2015.09.017.
   PubMed Web of Science ®Google Scholar
• Laheurte C, Galaine J, Beziaud L, Dosset M, Kerzerho J, Jacquemard C, Gaugler B, Ferrand C, Dormoy A, Aubin F, et al. Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients. Oncoimmunology. 2016;5(5):e1137416. doi: 10.1080/2162402X.2015.1137416.
   PubMed Web of Science ®Google Scholar